SOLICITATION NOTICE
B -- Determine serum levels of leptin by ELISA procedures in kidney cancer cases.
- Notice Date
- 8/20/2008
- Notice Type
- Presolicitation
- NAICS
- 622110
— General Medical and Surgical Hospitals
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-80196-MM
- Archive Date
- 9/14/2008
- Point of Contact
- Ashley L. Virts, , Melissa P Marino, Phone: 301-402-4509
- E-Mail Address
-
virtsa@mail.nih.gov, marinome@mail.nih.gov
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB) plans to procure on a sole source basis with Jewish General Hospital; Lady David Institute, Pollack Research Lab – E 423; 3755 Cote Ste. Catherine Rd.; Montreal, Quebec H3T 1E2 services regarding serum levels of leptin, an adiponectin by standard ELISA procedures in 852 kidney cancer cases. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1 (b) (1). The North American Industry Classification System Code is 622110 and the business size standard is $31.5M employees. The incidence of renal cell carcinoma (RCC), the most common histological type of kidney cancer, has increased rapidly in the United States, particularly among African Americans. The prevalence of obesity in this country has also increased over the past few decades. Despite a well-established link between obesity and kidney cancer, the mechanism through which obesity acts to increase cancer risk has yet to be definitively established. Recently, adipokines, biologically active peptides secreted by adipocytes, have been identified and proposed as the potential link between obesity and cancer. Although several of these markers have demonstrated promising results as predictors of risk and progression in several other obesity-related cancers, it is yet to be determined whether these biomarkers may explain the association between obesity and kidney cancer. The purpose of the current procurement is to determine serum levels of leptin and adiponectin by standard ELISA procedures in 852 kidney cancer cases, 820 controls, and an additional 100 blinded quality control samples. In this study, we propose to measure serum leptin and adiponectin levels by ELISA in kidney cancer cases and controls from a large case-control study. The purpose of this study is to investigate whether serum adipokines levels are associated with kidney cancer survival; and to characterize adipokines levels and relate them to body mass index and other health indicators. Extensive questionnaire data and biologic samples have already been collected for these study populations. Knowledge gained from this study will provide important information on characterizing adipokines levels and its relation to kidney cancer. The Period of Performance shall be twelve months from date of award. The Jewish General Hospital at the Lady Davis Institute has extensive experience and specializes in examining circulating levels of hormones and other analytes implicated in carcinogenesis with high assay precision. The Jewish General Hospital is capable of measuring serum adipokines with high-throughput to analyze the needed number of samples. Adiponectin and leptin are both established assays in the Jewish General Hospital. To simplify the control of laboratory operations and guarantee standardized quality control procedures among studies from NCI, it is essential to conduct the adipokine assays at the same lab. There is no other source known to the NCI that can complete the requirements of this study. This is not a solicitation for competitive quotations. However, if any interested party believes it can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office by 11:00 AM EST on August 30, 2008. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Marino, Contract Specialist at marinome@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference NCI-80196-MM on all correspondence
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=458e2f212279ed7037478e29f5336fa7&tab=core&_cview=1)
- Record
- SN01645873-W 20080822/080820221618-92461a2bf62b40008ce9f68917b86e10 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |